ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Roche will expand its capacity for biotechnology products through a new biotech center at its Basel headquarters and a new plant in Penzberg, Germany. Each project will cost about $300 million and will take three years to complete, the company says. Roche will tear down an existing chemical production building to make room for the Basel center. The new facilities will be used to produce monoclonal antibodies for the anticancer medicines Avastin (bevacizumab) and Herceptin (trastuzumab). Some 150 new jobs will be created at each site.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter